GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults.
The mRNA-based candidate generated stronger immune responses than currently approved standard- and high-dose flu vaccines, according to GSK (NYSE:GSK). Its design also targets two important surface proteins on the influenza virus rather than focusing on one. These findings support further development, but GSK must still demonstrate the vaccine’s performance in a larger late-stage study.
Bull Case
The mid-stage results provide the clearest reason for advancing the program. GSK said its candidate generated stronger immune responses than approved standard-dose vaccines in younger adults and approved high-dose vaccines in older adults. Showing stronger responses across both age groups is particularly encouraging because older adults commonly receive high-dose shots intended to produce a more robust immune response. GSK’s candidate also uses a differentiated two-target approach. It is designed to generate immune responses against haemagglutinin and neuraminidase, which are two key proteins found on the surface of the influenza virus.
According to GSK, the late-stage study will be the first for an mRNA seasonal flu vaccine designed to target both proteins, and the company believes this approach could improve protection and reduce transmission. Those potential advantages remain to be established in late-stage testing, but they give the vaccine a clear scientific rationale beyond using the mRNA platform alone.
The program is also moving forward quickly. GSK intends to begin the late-stage trial in September 2026 rather than waiting until a later influenza season. Advancing the candidate promptly could help the company gather the evidence needed to determine whether its mid-stage immune-response advantage translates into a clinically meaningful benefit. The trial is also part of a wider effort to accelerate GSK’s pipeline. Following a portfolio review by CEO Luke Miels, the company plans to initiate more than 20 late-stage studies by the end of 2026. The strategy is intended to speed drug development as GSK prepares for approaching patent expirations. If the flu candidate succeeds, it could add another late-stage opportunity to a pipeline that management is attempting to strengthen before those patent losses become more consequential.
Bear Case
Stronger immune responses do not necessarily establish that the vaccine will prevent more influenza cases, reduce severe illness, or lower transmission. In addition, GSK has not provided the planned late-stage trial’s enrollment, completion date, or expected regulatory-submission timeline. Investors therefore cannot determine how long the program may take to reach regulators or the market.
GSK is also entering late-stage development after another mRNA flu vaccine has already reached the United States. In August 2026, the FDA approved Moderna’s mFlusiva for people aged 50 and older, making it the first authorized mRNA-based seasonal flu vaccine. GSK’s two-protein design may be different, but that distinction will matter commercially only if late-stage evidence supports it.
The broader pipeline initiative also creates execution pressure. Beginning more than 20 late-stage studies by year-end demonstrates ambition, but each program will require clinical resources and carries its own risk of failure.
Conclusion
GSK’s mid-stage results give its mRNA flu program a credible foundation for late-stage testing. Stronger immune responses across younger and older adults, combined with the two-protein design, make the candidate scientifically interesting.
The decisive evidence has not arrived, however. GSK still needs to demonstrate whether those immune responses produce meaningful clinical protection and support regulatory approval. The September trial will determine whether the candidate can become an important part of GSK’s accelerated pipeline, or remain a promising experimental program.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center